21:18 , Feb 16, 2018 |  BioCentury  |  Finance

Global access

Vivo Capital could help InnoCare Pharma Ltd. seek global development partners as the Chinese cancer and autoimmune company evaluates its first four candidates in the clinic. Vivo, a new investor, led an untranched $55 million...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

BioDuro, BioAtla deal

BioAtla and BioDuro partnered to advance two undisclosed mAbs through preclinical and Phase I trials in China. The companies will out-license the compounds to Chinese biopharmaceutical companies for further development and commercialization in China. BioAtla...
08:00 , Feb 24, 2014 |  BioCentury  |  Tools & Techniques

Bigger is better

X-Chem Inc. has developed a screening platform and library of DNA-encoded small molecules that enable the identification of high-quality lead candidates against difficult targets. So far, the platform has yielded a handful of discovery deals,...
07:00 , Apr 8, 2013 |  BioCentury  |  Emerging Company Profile

MAB Discovery: Monitoring maturation

MAB Discovery GmbH is using wild-type animals and blood samples collected at multiple time points during antibody maturation to generate diverse sets of antibodies with high selectivity and affinity for a target antigen. The company...
08:00 , Nov 15, 2012 |  BC Innovations  |  Cover Story

Bringing macrocycles full circle

The opportunity afforded by macrocycles and constrained peptides to open up vast new therapeutic real estate is rivaled only by the challenge of puzzling out the basic science underlying these molecules. Now, a think tank...
07:00 , Sep 5, 2011 |  BioCentury  |  Strategy

Back to School: Innovation & collaboration

Since the economic downturn of 2008, doom has become ingrained in the biopharma narrative. According to the mantra, budgets for great science have flatlined. New startups can't find VC money to translate great science because...
08:00 , Nov 15, 2010 |  BioCentury  |  Strategy

Innovators pick China

Five years after he co-founded BioDuro LLC , a contract research organization operating in China, John Oyler is at it again. But this time, his new team is doing what would have been almost unthinkable...
07:00 , May 3, 2010 |  BioCentury  |  Strategy

Doorway to discovery in China

As big pharma looks to slim down, they have been outsourcing increasing amounts of discovery work. In response, two of the largest CROs, Charles River Laboratories International Inc. and PPD Inc. , have acquired Chinese...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

BioDuro, PPD Inc. deal

PPD completed its previously announced acquisition of drug discovery services company BioDuro for about $77 million in cash (see BioCentury, Nov. 23). BioDuro LLC , San Diego, Calif.   PPD Inc. (NASDAQ:PPDI), Wilmington, N.C.  ...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

PPD Inc., BioDuro, J&J deal

Johnson & Johnson's Janssen Pharmaceutica N.V. subsidiary granted PPD rights to develop and commercialize two undisclosed compounds PPD describes as "Phase II-ready." The compounds include a mu opioid receptor agonist and a delta opioid receptor...